Form 4: Forbion Growth Opportunities Fund I Increases Stake in enGene Holdings Inc.
SEC Form 4
Forbion Growth Opportunities Fund I reports multiple purchases of enGene Holdings Inc. common shares between December 2023 and October 2024, increasing its holdings.
Summary
- Forbion Growth Opportunities Fund I Cooperatief U.A. has filed a Form 4 detailing changes in beneficial ownership of enGene Holdings Inc. [ENGN] common shares.
- The fund, along with related entities Forbion Growth Management B.V. and Forbion Growth Sponsor FEAC I B.V., has been actively purchasing shares.
- Transactions occurred on multiple dates, including 12/27/2023, 12/28/2023, 12/29/2023, 09/27/2024, 09/30/2024, and throughout October 2024.
- The purchases were made at varying prices, ranging from $5.9384 to $9.0905 per share.
- As a result of these transactions, Forbion Cooperatief directly holds 2,470,633 common shares, and Forbion Growth Sponsor FEAC I B.V. indirectly holds 3,765,932 shares.
- The reporting persons disclaim beneficial ownership of the securities reported, except to the extent of their pecuniary interest.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating increased investment, but without further context, it's difficult to gauge the overall impact.
Positives
- The increased stake by Forbion Growth Opportunities Fund I could be interpreted as a sign of confidence in enGene Holdings Inc.'s future prospects.
- Active purchasing may provide price support for the stock.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of insiders and major shareholders.
Stakeholder Impact
- Shareholders may view the increased stake positively.
- The increased stake may impact the share price.
Key Dates
| Date | Description |
|---|---|
| 12/27/2023 | Purchase of 2,750 common shares at a weighted average price of $7.1678. |
| 12/28/2023 | Purchase of 5,050 common shares at a weighted average price of $7.6885. |
| 12/29/2023 | Purchase of 400 common shares at $8.3 and 9,620 common shares at a weighted average price of $9.0905. |
| 09/27/2024 | Purchase of 38,396 common shares at a weighted average price of $5.9384 and 3,243 common shares at a weighted average price of $6.3794. |
| 09/30/2024 | Purchase of 341,332 common shares at a weighted average price of $6.338. |
| 10/01/2024 | Purchase of 35,279 common shares at a weighted average price of $6.4389. |
| 10/02/2024 | Purchase of 10,153 common shares at a weighted average price of $6.3722. |
| 10/03/2024 | Purchase of 5,769 common shares at a weighted average price of $6.4824. |
| 10/04/2024 | Purchase of 5,997 common shares at a weighted average price of $6.5436. |
| 10/07/2024 | Purchase of 11,844 common shares at a weighted average price of $6.546. |
| 10/08/2024 | Purchase of 800 common shares at a weighted average price of $6.5981. |
| 10/18/2024 | Date of the report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.